article thumbnail

ElevateBio and Affini-T collaborate to develop T cell therapies

Pharmaceutical Technology

Affini-T’s platform can choose and engineer the correct immune cells to create a lasting and coordinated immune response in the immunosuppressive tumour microenvironment. To act on oncogenic driver mutations, Affini-T is using engineered T-cell therapies with synthetic biology and gene editing enhancements.

article thumbnail

FDA fast tracks type 1 diabetes cell therapy from Vertex

pharmaphorum

That is an approach that has been tried in other groups, but so far efforts have been impeded by difficulties in producing enough cells of sufficient quality and protecting them from the patient’s immune response. That implantable technology was at the heart of the Semma acquisition.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

How Researchers Stumbled Upon an Arthritis Vaccine Just in Time for World Arthritis Day

XTalks

The vaccine was tested in rats and showed strong, immediate and long-lasting immune responses to confer protection against the disease. is an autoantigen, which means it is an endogenous antigen that triggers an immune response in the body. as a potential trigger for rheumatoid arthritis.

Vaccine 105
article thumbnail

Vycellix CEO to Present its Universal Cell Program (VY-UC) for Off-the-Shelf NK Cell Therapy at Allogeneic Cell Therapies Summit

BioTech 365

-Proof-of-concept achieved for VY-UC to engineer donor cells without the complexities of gene-editing -Novel platform abrogates cellular immune response and obviates the need for immunosuppressive drugs TAMPA, Fla. & & STOCKHOLM–(BUSINESS WIRE)–#celltherapy–Vycellix, Inc.,

article thumbnail

Moderna’s COVID-19 vaccine trial; Freenome secures $270 M; CRISPR treats obesity in mice; Breast cancer research updates

Delveinsight

Moderna’s COVID-19 vaccine triggers an immune response in older adults. Now, a research team that is led by scientists at Harvard University have used the CRISPR-Cas9 gene-editing technology to engineer human white fat so that it shows the properties of brown fat.

Vaccine 53
article thumbnail

Advances in Genetic Medicine May Be Outpacing Some Clinicians’ Understanding, But Pharmaceutical Marketers Can Do Much to Address the Problem

Pharma Marketing Network

those that modify the expression of an individual’s genes or repair abnormal genes) has entered clinical practice, including 11 RNA therapeutics, 2 in vivo gene therapies, and 2 gene-modified cell therapies. Almost two decades after the human genome was sequenced, a trickle of new genetic medicines (i.e.,

article thumbnail

Using bispecific antibodies to advance cancer immunotherapy

pharmaphorum

The more targeted, bispecific functionality of bsAbs broadens the reach of antibody-mediated therapies against both solid and haematological cancers, creating novel approaches that can induce a tumour-specific immune response, target immune checkpoints, or improve payload delivery to tumour cells (Fig.